MNKKQ Stock
Price Chart
MNKKQ Financial and Trading Overview
stock price | |
Previous Close | 0.02 |
Open | 0.02 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.02 - 0.02 |
52 Week Range | 0.001 - 0.36 |
Volume | 290.54K |
Avg. Volume | 344.47K |
Market Cap | 1.69M |
Beta (5Y Monthly) | 2.818627 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MNKKQ Valuation Measures
Enterprise Value | 82.67M |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.00076714775 |
Price/Book (mrq) | 0.00330033 |
Enterprise Value/Revenue | 0.037 |
Enterprise Value/EBITDA | 0.105 |
Trading Information
Stock Price History
Beta (5Y Monthly) | 2.818627 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 0.36 |
52 Week Low | 0.001 |
50-Day Moving Average | 0.06 |
200-Day Moving Average | 0.12 |
MNKKQ Share Statistics
Avg. Volume (3 month) | 344.47K |
Avg. Daily Volume (10-Days) | 0 |
Shares Outstanding | 84.72M |
Float | 78.63M |
Short Ratio | 10.58 |
% Held by Insiders | 11.18% |
% Held by Institutions | 0.40% |
Shares Short | 41.72M |
Short % of Float | 50.07% |
Short % of Shares Outstanding | 49.32% |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | December 31, 2021 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -32.47% |
Operating Margin (ttm) | 5.21% |
Gross Margin | 40.36% |
EBITDA Margin | 35.72% |
Management Effectiveness
Return on Assets (ttm) | 0.77% |
Return on Equity (ttm) | -108.58% |
Income Statement
Revenue (ttm) | 2.21B |
Revenue Per Share (ttm) | 26.08 |
Quarterly Revenue Growth (yoy) | -12.50% |
Gross Profit (ttm) | 891.7M |
EBITDA | 789M |
Net Income Avi to Common (ttm) | -723500032 |
Diluted EPS (ttm) | -7.869 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.34B |
Total Cash Per Share (mrq) | 15.87 |
Total Debt (mrq) | 1.42B |
Total Debt/Equity (mrq) | 453.1 |
Current Ratio (mrq) | 1.189 |
Book Value Per Share (mrq) | 6.06 |
Cash Flow Statement
Operating Cash Flow (ttm) | 455.4M |
Levered Free Cash Flow (ttm) | 855.04M |
Profile of
Country | |
State | N/A |
City | Dublin |
Address | College Business & Technology Park |
ZIP | 15 |
Phone | 353 1 696 0000 |
Website | https://www.mallinckrodt.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 2778 |
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Q&A For Stock
What is a current MNKKQ stock price?
MNKKQ stock price today per share is .
How to purchase stock?
You can buy MNKKQ shares on the exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ?
The stock symbol or ticker of is MNKKQ.
Which industry does the company belong to?
The industry is Drug Manufacturers-Specialty & Generic.
How many shares does have in circulation?
The max supply of shares is 0.
What is Price to Earnings Ratio (PE Ratio)?
PE Ratio is 0.00000000 now.
What was earnings per share over the trailing 12 months (TTM)?
EPS is 0 over the trailing 12 months.
Which sector does the company belong to?
The sector is Healthcare.